The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
06 2019
Historique:
received: 14 08 2018
accepted: 23 01 2019
pubmed: 30 1 2019
medline: 17 6 2020
entrez: 30 1 2019
Statut: ppublish

Résumé

Replication fork stability during DNA replication is vital for maintenance of genomic stability and suppression of cancer development in mammals. ATR (ataxia-telangiectasia mutated [ATM] and RAD3-related) is a master regulatory kinase that activates the replication stress response to overcome replication barriers. Although many downstream effectors of ATR have been established, the upstream regulators of ATR and the effect of such regulation on liver cancer remain unclear. The ubiquitin conjugase BRUCE (BIR Repeat containing Ubiquitin-Conjugating Enzyme) is a guardian of chromosome integrity and activator of ATM signaling, which promotes DNA double-strand break repair through homologous recombination. Here we demonstrate the functions for BRUCE in ATR activation in vitro and liver tumor suppression in vivo. BRUCE is recruited to induced DNA damage sites. Depletion of BRUCE inhibited multiple ATR-dependent signaling events during replication stress, including activation of ATR itself, phosphorylation of its downstream targets CHK1 and RPA, and the mono-ubiquitination of FANCD2. Consequently, BRUCE deficiency resulted in stalled DNA replication forks and increased firing of new replication origins. The in vivo impact of BRUCE loss on liver tumorigenesis was determined using the hepatocellular carcinoma model induced by genotoxin diethylnitrosamine. Liver-specific knockout of murine Bruce impaired ATR activation and exacerbated inflammation, fibrosis and hepatocellular carcinoma, which exhibited a trabecular architecture, closely resembling human hepatocellular carcinoma (HCC). In humans, the clinical relevance of BRUCE down-regulation in liver disease was found in hepatitis, cirrhosis, and HCC specimens, and deleterious somatic mutations of the Bruce gene was found in human hepatocellular carcinoma in the Cancer Genome Atlas database. Conclusion: These findings establish a BRUCE-ATR signaling axis in accurate DNA replication and suppression of liver cancer in mice and humans and provides a clinically relevant HCC mouse model.

Identifiants

pubmed: 30693543
doi: 10.1002/hep.30529
pmc: PMC6541504
mid: NIHMS1008475
doi:

Substances chimiques

BIRC6 protein, mouse 0
Inhibitor of Apoptosis Proteins 0
Tumor Suppressor Proteins 0
Atr protein, mouse EC 2.7.1.-
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2608-2622

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM109768
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA117846
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA158323
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES006096
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR027015
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA129537
Pays : United States

Informations de copyright

© 2019 by the American Association for the Study of Liver Diseases.

Références

Biochem Biophys Res Commun. 1999 Nov 2;264(3):847-54
pubmed: 10544019
Mol Cell. 2001 Feb;7(2):249-62
pubmed: 11239454
Carcinogenesis. 2001 Dec;22(12):2023-31
pubmed: 11751435
Science. 2003 Jun 6;300(5625):1542-8
pubmed: 12791985
Mol Cell. 2004 Jun 18;14(6):801-11
pubmed: 15200957
Genes Dev. 2004 Aug 15;18(16):1958-63
pubmed: 15314022
Mol Cell Biol. 2004 Nov;24(21):9339-50
pubmed: 15485903
Nat Genet. 2004 Dec;36(12):1306-11
pubmed: 15565109
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):565-70
pubmed: 15640352
Hum Mol Genet. 2005 Mar 1;14(5):693-701
pubmed: 15661754
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Nat Rev Cancer. 2006 Sep;6(9):674-87
pubmed: 16929323
Nat Cell Biol. 2009 Jan;11(1):65-70
pubmed: 19079246
Nat Rev Cancer. 2011 Jun 24;11(7):467-80
pubmed: 21701511
Mol Cell. 2011 Jul 22;43(2):192-202
pubmed: 21777809
Genes Dev. 2012 Jul 1;26(13):1393-408
pubmed: 22751496
Cancer Cell. 2012 Jul 10;22(1):5-6
pubmed: 22789533
Cancer Cell. 2012 Jul 10;22(1):106-16
pubmed: 22789542
Mol Oncol. 2013 Apr;7(2):206-23
pubmed: 23428636
Biochim Biophys Acta. 2013 Oct;1833(10):2126-34
pubmed: 23742842
Cold Spring Harb Perspect Biol. 2013 Sep 01;5(9):null
pubmed: 24003211
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
Mol Cell. 2014 Jan 23;53(2):235-246
pubmed: 24332808
DNA Repair (Amst). 2014 Jul;19:135-42
pubmed: 24768452
Hepatology. 2014 Nov;60(5):1767-75
pubmed: 24839253
Biomed Res Int. 2014;2014:153867
pubmed: 24877058
Mol Cell Biol. 2014 Nov;34(21):3939-54
pubmed: 25135477
Nat Struct Mol Biol. 2015 Mar;22(3):242-7
pubmed: 25643322
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1210-9
pubmed: 25733871
Lab Anim. 2015 Apr;49(1 Suppl):59-69
pubmed: 25835739
Nat Rev Cancer. 2015 May;15(5):276-89
pubmed: 25907220
Cell Cycle. 2015;14(12):1809-22
pubmed: 26083937
Oncogene. 2016 May 5;35(18):2279-86
pubmed: 26364595
PLoS One. 2015 Dec 18;10(12):e0144957
pubmed: 26683461
Nat Rev Mol Cell Biol. 2016 Jun;17(6):337-49
pubmed: 27145721
Oncotarget. 2016 Jun 7;7(23):33557-70
pubmed: 27248179
Carcinogenesis. 2017 Jan;38(1):2-11
pubmed: 27838634
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Cell. 2017 Feb 9;168(4):644-656
pubmed: 28187286
Nucleic Acids Res. 2017 Sep 6;45(15):8859-8872
pubmed: 28666352
Curr Biol. 2017 Sep 25;27(18):R986-R988
pubmed: 28950089
iScience. 2018 Apr 27;2:123-135
pubmed: 29888761
J Cell Biol. 1998 Jun 15;141(6):1415-22
pubmed: 9628897

Auteurs

Chunmin Ge (C)

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH.

Chrystelle L Vilfranc (CL)

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH.

Lixiao Che (L)

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH.

Raj K Pandita (RK)

Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX.

Shashank Hambarde (S)

Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX.

Paul R Andreassen (PR)

Division of Experimental Hematology and Cancer Biology, Cincinnati Children Hospital Medical Center, Cincinnati, OH.

Liang Niu (L)

Department of Environmental Health, University of Cincinnati, Cincinnati, OH.

Olugbenga Olowokure (O)

Department of Internal Medicine, University of Cincinnati, Cincinnati, OH.

Shimul Shah (S)

University of Cincinnati College of Medicine, University of Cincinnati, Cincinnati, OH.

Susan E Waltz (SE)

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH.

Lee Zou (L)

Department of Pathology, Massachusetts General Hospital Cancer Center; Harvard Medical School, Charlestown, MA.

Jiang Wang (J)

Department of Pathology, University of Cincinnati, Cincinnati, OH.

Tej K Pandita (TK)

Department of Radiation Oncology, Houston Methodist Research Institute, Houston, TX.

Chunying Du (C)

Department of Cancer and Cell Biology, University of Cincinnati, Cincinnati, OH.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH